Isis Pharmaceuticals To Provide Update On FDA Approval Of KYNAMRO™ (mipomersen)

      Isis Pharmaceuticals To Provide Update On FDA Approval Of KYNAMRO™

Conference Call And Webcast On Wednesday, January 30 at 09:30 a.m. ET

PR Newswire

CARLSBAD, Calif., Jan. 29, 2013

CARLSBAD, Calif., Jan. 29, 2013 /PRNewswire/ --Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS) announced today that it will conduct a conference call and
webcast to provide an update on the U.S. Food and Drug Administration (FDA)
approval of the marketing of KYNAMRO™ (mipomersen) for the treatment of
patients with Homozygous Familial Hypercholesterolemia (HoFH).

At 09:30 a.m. Eastern Time, Wednesday, January 30, 2013, Isis will conduct a
live audio webcast and conference call. Interested parties may listen to the
call by dialing 1-866-323-2841, or 1-617-500-8943 for international callers,
and refer to conference ID 95497110. The webcast can be accessed at A webcast replay will be available for a limited time at
the same address.

Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 28 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, is commercializing Isis' lead product,
KYNAMRO™, in the United States for the treatment of patients with HoFH.
Genzyme is also pursuing marketing approval of KYNAMRO in other markets,
including Europe. Isis' patents provide strong and extensive protection for
its drugs and technology. Additional information about Isis is available at

This press release includes forward-looking statements regarding Isis'
collaboration with Genzyme, a Sanofi company, and the development, activity,
therapeutic benefit, safety and commercial potential of KYNAMRO in treating
patients with homozygous FH. Any statement describing Isis' goals,
expectations, financial or other projections, intentions or beliefs, including
the planned commercialization of KYNAMRO, is a forward-looking statement and
should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a business
around such drugs. Isis' forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on facts and
factors currently known by Isis. As a result, you are cautioned not to rely
on these forward-looking statements. These and other risks concerning Isis'
programs are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31, 2011 and its most recent quarterly report
on Form 10-Q, which are on file with the SEC. Copies of these and other
documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.
KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.

Contact: D. Wade Walke, Ph.D., Executive Director, Corporate Communications
and Investor Relations, +1-760-603-2741; Amy Blackley, Ph.D., Associate
Director, Corporate Communications, +1-760-603-2772
Press spacebar to pause and continue. Press esc to stop.